Literature DB >> 20197133

Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response.

Danan Wang1, Jia Xu, Yonghui Feng, Ying Liu, S S Salum Mchenga, Fengping Shan, Jin-ichi Sasaki, Changlong Lu.   

Abstract

Tuberculosis is one of the leading causes of mortality from an infectious disease worldwide, however, the efficacy of BCG vaccine against adult pulmonary tuberculosis still remains instability. Therefore, it is an urgent work to develop both safe and effective vaccine to TB. To clarify the liposome encapsulated DNA vaccine was effectively working as a vaccine delivery system to evoke mucosal intestinal immune responses. A Mycobacterium pcDNA3.1(+)/Ag85A DNA was constructed and encapsulated into liposome. Ag85A protein antigen was observed to substantially express in the epithelium, microfold cells (M cells), dendritic cells (DCs) and Peyer's patches (pp) of the small intestine, respectively, after oral administration into C57BL/6 mice 3 times each 14 days interval. Furthermore, levels of IL-2 and IFN-gamma in the IELs isolated from the small intestine were markedly increased, IL-4 level was not significantly changed as compared to those in control group after oral administration of Ag85A DNA encapsulated in liposome, together with the augmented Ag85A-specific cytotoxicity of IELs, indicating a local Th1 dominant cellular immune response was elicited, and thus enhanced cytotoxicity of IELs as compared to those in control mice. Furthermore, sIgA level was also elevated in liposomal encapsulated Ag85A DNA immunized mice. These data indicated that oral vaccination with the liposomal-pcDNA 3.1(+)/Ag85A DNA is able to induce antigen specific mucosal cellular and humoral immune responses. Especially, cellular compartment in the epithelium of small intestine plays a key role on the regulation of immune response to eliminate TB. These findings have important understanding and possible implications for the design of new strategies based on oral DNA vaccine on regulation of immune response in protection against TB. Further study is clearly necessary to improve the effectiveness of Ag85A DNA vaccines against TB as compared with BCG. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197133     DOI: 10.1016/j.vaccine.2010.02.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Micro- and nanoparticulates for DNA vaccine delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-04

Review 3.  A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.

Authors:  Ahmad M Aldossary; Chinedu S M Ekweremadu; Ifunanya M Offe; Haya A Alfassam; Sooyeon Han; Vivian C Onyali; Chukwuebuka H Ozoude; Emmanuel A Ayeni; Chinekwu S Nwagwu; Abdulrahman A Halwani; Nada H Almozain; Essam A Tawfik
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

Review 4.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

5.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

Review 6.  Tuberculosis vaccine research in China.

Authors:  Douglas B Lowrie
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

7.  Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis.

Authors:  Jing Xiong; Ying-Hao Lin; Li-Hong Bi; Ji-De Wang; Yang Bai; Si-De Liu
Journal:  BMC Gastroenterol       Date:  2013-12-06       Impact factor: 3.067

8.  Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?

Authors:  Renata Monteiro-Maia; Rosa Teixeira de Pinho
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-09       Impact factor: 2.743

Review 9.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

10.  Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Authors:  Wu Li; Guangcun Deng; Min Li; Xiaoming Liu; Yujiong Wang
Journal:  Tuberc Res Treat       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.